Results 51 to 60 of about 798,481 (288)

Cellular effects of everolimus and sirolimus on podocytes. [PDF]

PLoS ONE, 2013
Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection.
Sandra Müller-Krebs, Lena Weber, Julia Tsobaneli, Lars P Kihm, Jochen Reiser, Martin Zeier, Vedat Schwenger   +6 more
doaj   +1 more source

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy [PDF]

, 2009
Mammalian target of rapamycin (mTOR) is a key regulator of cell growth that associates with raptor and rictor to form the mTOR complex 1 (mTORC1) and mTORC2, respectively.
Richard-Bulteau, Hélène, Arnaud Ferry, Pende, Mario, Rüegg, Markus,, Hantaï, Daniel, Mario Pende, Le-Marchand-Brustel, Yannick, Kozma, Sara, Corneloup, Claudine, Laetitia Mazelin, Ferrier, Bernard, Hervé Sanchez, Koulmann, Nathalie, Claudine Corneloup, Bigard, Xavier, Daniel Hantaï, Rüegg, Markus, A., Hélène Richard-Bulteau, Mueller, Matthias, Bauché, Stéphanie, Moncollin, Vincent, Roceri, Mila, Jean-François Tanti, Conjard-Duplany, Agnès, Vignaud, Alban, Alban Vignaud, Stéphanie Bauché, Xavier Bigard, Freyssenet, Damien, Agnès Conjard-Duplany, Tanti, Jean-François, Laurent Schaeffer, Thomas, George, Mazelin, Laetitia, Defour, Aurélia, Aurélia Defour, Romanino, Klaas, Damien Freyssenet, Yannick Le-Marchand-Brustel, Bernard Ferrier, Nathalie Koulmann, George Thomas, Sanchez, Hervé, Baas, Dominique, Klaas Romanino, Sara C. Kozma, Mila Roceri, Kozma, Sara C., Rüegg, Markus A., Yann-Gaël Gangloff, Schaeffer, Laurent, Matthias Mueller, Vincent Moncollin, Markus A. Rüegg, Ferry, Arnaud, Gangloff, Yann-Gaël, Dominique Baas, Risson, Valérie, Valérie Risson   +58 more
core   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling [PDF]

, 2009
BackgroundMammalian target of rapamycin complex 1 (mTORC1) is a protein kinase that relays nutrient availability signals to control numerous cellular functions including autophagy, a process of cellular self-eating activated by nutrient depletion ...
Trevor C F Tsang, Roberge, Michel, Bruno D Fonseca, Patrick Lajoie, Tsang, Trevor C. F., Lajoie, Patrick, Proud, Christopher G., Aruna D Balgi, Michel Roberge, Tsang Trevor C. F., Ivan R Nabi, Lajoie, P., Nabi Ivan R., Fonseca, B., Balgi, Aruna D., Fonseca, Bruno D., Proud, C., Tsang, T., Balgi, A., Nabi, Ivan R., Roberge, M., Balgi Aruna D., Proud Christopher G., Lajoie Patrick, Roberge Michel, Donohue, Elizabeth, Christopher G Proud, Donohue Elizabeth, Nabi, I., Fonseca Bruno D., Donohue, E., Elizabeth Donohue   +31 more
core   +2 more sources

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Function of mTOR complex 1 and 2 in skeletal muscle [PDF]

, 2009
Growth of an organ during development and during adaptation in the adult can be controlled by alterations either in the number or the size of cells. The two mechanisms are fundamentally different and require distinct regulation.
Bentzinger, Conrad Florian
core   +1 more source

mTOR Signaling in Metabolism and Cancer [PDF]

, 2020
The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and ...

core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Peripheral lysosomes recruit PLEKHG3 to focal adhesions and restrain protrusion dynamics

FEBS Letters, EarlyView.
Proximity‐dependent labeling at the LAMTOR complex revealed the Rho GEF PLEKHG3 as a lysosome‐proximal protein directing the study toward the influence of lysosome positioning on actin dynamics and cell motility. We show that PLEKHG3 colocalizes with lysosomes at focal adhesion sites and observe that forced peripheral dispersion of lysosomes hinders ...
Rainer Ettelt, Ana‐Maria Sandru, Georg Vucak, Sebastian Didusch, Biljana Riemelmoser, Karin Ehrenreiter, Markus Hartl, Lukas A. Huber, Manuela Baccarini   +8 more
wiley   +1 more source

PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy

Frontiers in Oncology, 2022
Esophageal squamous cell carcinoma (ESCC), is the most common type of esophageal cancer worldwide, mainly occurring in the Asian esophageal cancer belt, including northern China, Iran, and parts of Africa.
Qian Luo, Qian Luo, Ruijuan Du, Ruijuan Du, Wenting Liu, Wenting Liu, Guojing Huang, Zigang Dong, Zigang Dong, Zigang Dong, Zigang Dong, Xiang Li, Xiang Li, Xiang Li, Xiang Li   +14 more
doaj   +1 more source